Example: Heart Attack

Search clinical trials for: Nicotinic Agonists

Total 959 results

NCT02111551

Terminated

Phase I Nicotinic Agonist Treatment Trial for Autism

Conditions: Autism
NCT02458313

Recruiting

Nicotinic Agonist Effects on BMI and Neuronal Response

Conditions: Obesity
NCT00100165

Completed

Phase 2 Trial of a Nicotinic Agonist in Schizophrenia

Conditions: Schizophrenia
NCT00109564

Completed

A Safety and Efficacy Study of Ispronicline (TC-1734-112) in Subjects With Age Associated Memory Impairment (AAMI)

Conditions: Age-Related Memory Disorders
NCT00320736

Completed

Galantamine for Cognition in People With Schizophrenia

Conditions: Schizophrenia; Schizoaffective Disorder
NCT02473562

Terminated

Varenicline Treatment for Excessive Daytime Sleepiness in Parkinson's Disease

Conditions: Parkinson's Disease
NCT01480232

Terminated

A Safety and Cognitive Function Study of EVP-6124 Versus Placebo in Subjects With Nicotine Dependence

Conditions: Nicotine Dependence; Smoking Cessation
NCT01716975

Completed

Study of EVP-6124 (Alpha-7 nAChR) as an Adjunctive Pro-Cognitive Treatment in Schizophrenia Subjects on Chronic Stable Atypical Antipsychotic Therapy

Conditions: Schizophrenia; Impaired Cognition
NCT01714661

Completed

Study of EVP-6124 (Alpha-7 nAChR) as an Adjunctive Pro-Cognitive Treatment in Schizophrenia Subjects on Chronic Stable Atypical Antipsychotic Therapy

Conditions: Schizophrenia; Impaired Cognition
NCT01073228

Completed

Safety and Cognitive Function Study of EVP-6124 in Patients With Mild to Moderate Alzheimer's Disease

Conditions: Alzheimer's Disease; Central Nervous System Diseases; Cognition
NCT00968851

Completed

Safety and Cognitive Function Study of EVP-6124 in Patients With Schizophrenia

Conditions: Schizophrenia; Central Nervous System Diseases; Cognition
NCT01714713

Completed

A 26-Week Extension Study of EVP-6124 (Alpha-7 nAChR) as an Adjunctive Pro-Cognitive Treatment in Schizophrenia Subjects on Chronic Stable Atypical Antipsychotic Therapy

Conditions: Schizophrenia; Impaired Cognition
NCT00766363

Completed

Safety, Tolerability, and Pharmacokinetic Study of EVP-6124 in Patients With Alzheimer's Disease

Conditions: Alzheimer's Disease; Central Nervous System Diseases
NCT02432066

Withdrawn

Effects of GTS-21 on Smoking Behavior and Neurocognitive Functions

Conditions: Tobacco Use Disorder
NCT01756053

Terminated

Effects of ABT-089 on Smoking Abstinence Symptoms and Reward

Conditions: Nicotine Addiction
NCT02552147

Completed

Nicotinic Cholinergic Modulation as a Novel Treatment Strategy for Aggression Associated With Autism

Conditions: Autism Spectrum Disorder; Aggression; Irritability
NCT01170338

Unknown status

Safety and Efficacy of the Novel Selective Nicotinic Receptor Partial Agonist, CHANTIX (Varenicline) in Patients With Acute Coronary Syndrome

Conditions: Smoking; Acute Coronary Syndrome
NCT01764243

Completed

Safety and Efficacy of MT-4666

Conditions: Alzheimer's Disease
NCT00783068

Completed

Anti-inflammatory Effects of GTS-21 After LPS

Conditions: Endotoxemia; Sepsis; Vagal Activity
NCT00523445

Completed

The Effects of Varenicline on Cognitive Function in Patients With Schizophrenia

Conditions: Schizophrenia
NCT03904186

Recruiting

Effectiveness of an Integrated Treatment to Address Smoking Cessation and Anxiety/ Depression in People Living With HIV

Conditions: Human Immunodeficiency Virus; Smoking Cessation; Smoking, Cigarette; Smoking; Anxiety; Depression; Nicotine Dependence
NCT04191278

Not yet recruiting

Mobile Health Interventions for Medication Adherence Among PLWH

Conditions: HIV/AIDS; Smoking; Smoking Cessation; HIV
NCT03557294

Recruiting

Varenicline OTC Trial on Efficacy and Safety

Conditions: Tobacco Dependence; Withdrawal Symptoms; Smoking Cessation
NCT00621777

Completed

A Study of Varenicline for Prevention of Relapse to Smoking in Patients With Schizophrenia or Bipolar Disorder

Conditions: Schizophrenia; Schizoaffective Disorder; Bipolar Disorder; Smoking
NCT04631874

Completed

A Clinical Trial to Compare Pharmacokinetics of the "CDFF0318" and "Champix Tab. 1mg"

Conditions: Smoking Cessation; Pharmacokinetics